Electrochemical bioplatform for the determination of the most common and carcinogenic human papillomavirus DNA.
J Pharm Biomed Anal
; 231: 115411, 2023 Jul 05.
Article
en En
| MEDLINE
| ID: mdl-37094410
ABSTRACT
Nucleic acid-based analytical bioplatforms have gained importance as diagnostic tests for genomics and as early detection tools for diseases such as cancer. In this context, we report the development of an amperometric bioplatform for the determination of a specific human papillomavirus type 16 (HPV16) sequence. The bioplatform utilizes an immune-nucleic acid hybrid-sandwich assay. A biotinylated RNA capture probe (RNAbCp), complementary to the selected HPV16 target DNA sequence, was immobilised on the surface of streptavidin coated magnetic microbeads (Strep-MBs). The RNA/DNA heteroduplex resulting from the hybridization of the RNAbCP and the HPV16 target sequence was recognised by a commercial antibody that specifically bound to the heteroduplex (AbDNA-RNA). A horseradish-peroxide labeled secondary antibody (antiIgG-HRP) was used for the detection of AbDNA-RNA. Relying on amperometric detection of the resulting HRP-labeled magnetic bioconjugates captured on screen-printed electrodes (SPCEs) in the presence of H2O2 and hydroquinone (HQ), the biotool achieved a low limit of detection (0.5 pM) for the synthetic HPV16 target DNA. In addition, the developed bioplatform was able to discriminate between HPV16 positive and negative human cancer cells using only 25 ng of amplified DNA in a test time of 45 min.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Técnicas Biosensibles
/
Neoplasias
Tipo de estudio:
Screening_studies
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article